肿瘤标志物在肺癌诊疗中的研究进展  

The Current Status of Tumor Markers in Lung Cancer

作　　者：郑名华 孙国栋[1] 张郧樊 杨建新[1] 

机构地区：[1]广东药学院,广东广州510006

出　　处：《中国医学创新》2016年第4期145-148,共4页Medical Innovation of China

摘　　要：肿瘤标志物的检测,对肺癌的早期诊断、临床分期、组织学分型、预后判断和疗效监测都具有重要价值。本文对癌胚抗原(CEA)、胃泌素释放肽前体(Pro GRP)、细胞角蛋白19片段(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、鳞状上皮细胞癌抗原(SCC)等肺癌肿瘤标志物的研究现状进行概述。The determination of tumor markers is of great value for early diagnosis. It is not only helpful in clinical staging and classification of pathological types in patients with lung cancer, but also useful in evaluation of prognosis and response to treatment.This article reviews the current status of tumor markers in lung cancer, such as CEA, ProGRP, CYFRA21-1, NSE, SCC, and soon.

关 键 词：肺癌 肿瘤标志物 诊断 

分 类 号：R734.2[医药卫生—肿瘤]